Matteo Scarabelli | Market Access, Associated Director
EFPIA - European Federation of Pharmaceutical Industries and Associations
After a Phd in Philosophy and a first experience in a competitiveness-focus Brussels think tank, Matteo Scarabelli joined Eurordis - the European Organisation of rare disease patients - to be responsible for the involvement of patients in research and decision making for orphan drugs. For two years now, he has been working at the heart of the pharmaceutical industry’s efforts to prepare for the new European HTA setting and for its implementation into national pricing and reimbursement systems, as EFPIA Associate Director for Market Access.
Appearances:
Day 2 - Thursday 24 October @ 14:40
Public-Private Partnerships to accelerate development and boost innovation in Rare Diseases
- the evolving landscape of European health policy, this high-level panel brings together key stakeholders to address a critical yet often overlooked issue: the urgent need to enhance collaboration between European Reference Networks (ERNs) and industry in rare disease research. With a new EU leadership, this discussion comes at a pivotal moment to shape the future of rare disease policy and research prioritization.
- Leveraging public-private partnerships to accelerate innovation
- Proposals for a "sandbox" framework to facilitate agile collaborations
- Enhancing patient involvement in shaping research priorities
- Addressing funding challenges through novel mechanisms
As we anticipate the Hungarian Presidency's focus on rare diseases and look ahead to the Polish and Danish Presidencies, this panel will generate actionable insights to inform policy recommendations. Our goal is to catalyze momentum for an EU Rare Disease Action Plan that embraces the power of ERN-industry collaborations.
Despite progress, 95% of rare diseases still lack effective treatments, highlighting the imperative for innovative partnerships. This panel will explore how to overcome regulatory, funding, and capacity barriers that hinder optimal ERN-industry collaborations. By bringing together voices from patient advocacy, clinical research, policy, and industry, we aim to forge a path towards a more collaborative and efficient rare disease research ecosystem in Europe.
Key topics include:
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events